The standardization of disease activity assessment in patients with rheumatoid arthritis has improved the comparability of clinical trials. In 2011, the American College of Rheumatology and the European Alliance of Associations for Rheumatology provisionally endorsed the remission criteria for RA; since then, the criteria have been the subject of debate in terms of whether they are too lenient or too stringent. The Patient Global Assessment (PtGA) was one focus of the debate, with a higher PtGA threshold for the Boolean remission criteria being proposed. After validation in 2022, the revised Boolean criteria included a 2 cm PtGA cut-off, with the index-based definitions receiving full endorsement from the American College of Rheumatology and the European Alliance of Associations for Rheumatology.